ADC Therapeutics brings David Gilman onto its executive team

13 June 2022

Swiss antibody-drug conjugate specialist ADC Therapeutics (NYSE: ADCT) announced today it has appointed industry veteran David Gilman to the new role of chief business and strategy officer, reporting to chief executive Ameet Mallik effective July 1.

In this role, Mr Gilman will be responsible for all business development and portfolio strategy efforts globally and he will serve on the company’s executive leadership team.

“David Gilman is a seasoned business development and strategy executive who has an excellent track record within the life sciences industry,” said Ameet Mallik, who became president and CEO of ADC Therapeutics last month “We are excited to have David join our leadership team at this pivotal moment in the evolution of ADC Therapeutics,” he noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK